Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q16270
UPID:
IBP7_HUMAN
Alternative names:
IGFBP-rP1; MAC25 protein; PGI2-stimulating factor; Prostacyclin-stimulating factor; Tumor-derived adhesion factor
Alternative UPACC:
Q16270; B4E1N2; B7Z9W7; Q07822; Q53YE6; Q9UCA8
Background:
Insulin-like growth factor-binding protein 7 (IGFBP7), also known as IGFBP-rP1, MAC25 protein, and prostacyclin-stimulating factor, plays a crucial role in cellular processes by binding IGF-I and IGF-II with relatively low affinity. It is instrumental in stimulating prostacyclin (PGI2) production and enhancing cell adhesion.
Therapeutic significance:
IGFBP7's involvement in Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, a condition necessitating surgical intervention, underscores its potential as a target for therapeutic strategies. Understanding the role of IGFBP7 could open doors to innovative treatments for this and related diseases.